Biotech Crash: BioXcel Files Chapter 11, Stock Plunges 45%
Tap title to read story
BioXcel Therapeutics Inc. announced on August 28, 2026, that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the United States to facilitate a structured asset sale. The clinical-stage biopharmaceutical firm identified Teva Pharmaceuticals as the primary stalking-horse bidder for substantially all of its assets. The disclosure triggered a severe market reaction, driving BioXcel shares down approximately 45 percent in premarket trading and reducing its market capitalization to roughly $23 million, while Teva shares experienced a minor 1 percent decline. BioXcel, which leverages artificial intelligence to develop treatments in neuroscience and immuno-oncology, faced severe operational pressure driven by heavy commercialization overhead and persistent unprofitability, with net margins exceeding negative 9,550 percent. To maintain operations and preserve access to its FDA-approved acute agitation drug IGALMI during restructuring, BioXcel secured $19 million in debtor-in-possession financing from existing lenders while awaiting court review.
Timeline
- On April 05, 2022 IGALMI received official FDA approval for acute agitation.
- On June 30, 2023 Regulatory reviews flagged operational compliance and trial delays.
- On December 15, 2025 BioXcel restructured debt obligations to maintain clinical operations.
- On August 28, 2026 BioXcel initiated voluntary Chapter 11 bankruptcy filing proceedings.
- On August 28, 2026 BioXcel named Teva Pharmaceuticals primary stalking horse bidder.
- On August 28, 2026 BTAI stock dropped forty five percent in premarket trading.
- On August 28, 2026 Secured nineteen million dollars in debtor in possession funding.
- On September 15, 2026 Bankruptcy court considers approval of stalking horse bidding procedures.
- On November 14, 2026 FDA decisions expected on pending sNDA for BXCL501.
- On December 30, 2026 Bankruptcy court scheduled to finalize section 363 sale.
Sources
Wall Street Journal Pro Bankruptcy
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.






























